Novavax (NasdaqGS:NVAX) has been removed from multiple major Russell growth indices. The changes follow the latest Russell ...

Novavax (NVAX) has been removed from several Russell growth and small cap benchmarks, a shift that can influence index fund ...

Novavax (NVAX) ended the recent trading session at $9.35, demonstrating a -1.16% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.28%. Meanwhile, the Dow ...

Shares of Novavax Inc. NVAX slipped 1.16% to $9.35 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.20% to 25,870 ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax was close to going under. In early 2023, it warned investors that it might not have enough funds to finish the year. However, the biotech has made significant changes over the past 18 months.

Novavax's vaccine didn't enter the market until after the inoculations developed by Moderna and Pfizer had already taken dominant market shares. This meant it missed out on the biggest revenue ...

Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Novavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi (SNY) would invest $1.2 billion in a deal for Novavax's COVID-19 vaccine and take a ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.